Deals In Depth: February 2014
Actavis significantly improved its US presence though its $24 billion purchase of Forest Labs, while Myriad exercised its option to buy fellow molecular diagnostics company Crescendo. Public offerings – IPOs and follow-ons – dominated both biopharma and device financing.
You may also be interested in...
The US FDA and NIST have agreed to help industry modernize and update pharmaceutical manufacturing methods and to improve supply chain resilience.
Medtronic is sponsoring a trial to evaluate its adaptive deep brain stimulation technology, a unique feature of the Percept PC device for treating Parkinson’s disease.
The company cited lackluster efficacy in its decision to discontinue development of V590 and V591. It will instead develop two drugs to treat COVID-19.